Aroa Biosurgery Ltd · ASX:ARX
Aroa Biosurgery — Shareholder Meeting (August 2025)
22 slides from Aroa Biosurgery's shareholder meeting presentation, Aug 20, 2025
Slide 1: AGM 20 August 2025
For personal use only 20 AUGUST 2025 We ask for your patience and will be starting the meeting shortly
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer For personal use only This presentation (Presentation) is dated as per the front slide and has been prepared announcements lodged with ASX, and should rely solely on their own judgement, by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 revi
Slide 3: Your Board
Your Board AROA has a highly experienced board with healthcare, commercial, operational and financial experience For personal use only James Brian John Darla Philip Dr. Catherine John McLean Ward Diddams Hutton McCaw Mohr Pinion Chair, Founder, Independent Independent Non-executive Independent Indep
Slide 4: Joint Company Secretaries
Joint Company Secretaries For personal use only James Agnew Tracy Weimar Chief Financial Officer | 4
Slide 5: Agenda
Agenda For personal use only Chair’s CEO and Managing Financial Introduction Director’s Report Statements ? Resolutions Voting Questions | 5
Slide 6: Chair's Introduction
For personal use only JAMES MCLEAN Chair’s Introduction | 7
Slide 7: CEO and Managing Director's Report
For personal use only CEO and Managing Director’s Report | 8
Slide 8: Unlocking regenerative healing for everybody
Unlocking For personal use only regenerative healing for everybody World-leading outcomes Unmatched value Widespread impact | 9
Slide 9: World-leading outcomes: Lawlor Study
World-leading Lawlor Study outcomes For personal use only 120 30.0 DAYS 0 1.0 Patients Median time to Complications Median number of 100% tissue product applications Highly effective in the coverage and fill most compromised patients Patients were at high risk of amputation 93.8% 23.8% 47.7% 70.8% C
Slide 10: World-leading outcomes: Real-world evidence
World-leading Real-world evidence - DFU outcomes For personal use only UP TO UP TO 2,222 5.6 WEEKS 38% Total DFUs Faster closure with Increased probability of healing, Highly effective in the evaluated Endoform Natural* with Endoform Natural* most compromised patients Real-world evidence - VLU UP TO
Slide 11: World-leading outcomes: BRAVO Study
World-leading BRAVO Study outcomes For personal use only Ventral 92 2.6% Highly effective in the Hernia Participants Recurrence most compromised patients 77.2% 19.6% 83.7% ≥VHWG 2 ≥CDC 2 Prior abdominal surgery Unlocking regenerative healing for everybody DeNoto G 3rd, Ceppa EP, Pacella SJ, Sawyer M
Slide 12: Unmatched value: More for less
Unmatched value For personal use only More for less Patient Reduced Operational satisfaction hospital costs improvements Saving limbs, fewer procedures, Fewer interventions, Standardization simplifies fewer complications, earlier and complications, procedures, training and discharge, low risk of rec
Slide 13: Widespread impact
Widespread impact For personal use only Highly effective in multiple procedures & specialties Lower limb Trauma Hernia Breast NPWT Other Unlocking regenerative healing for everybody | 14
Slide 14: Financial Results FY25
Financial Results FY25 Reported YoY % For personal use only NZ$84.7m +23% Total Revenue Growing, profitable, & cashflow positive NZ$32.2m +38% (H2) Myriad Total Revenue 86% +1% Product Gross Margin NZ$74.5m Operating Expenses +9% NZ$4.2m +235% EBITDA NZ$22m Cash Unlocking regenerative healing for ev
Slide 15: FY26 Guidance
FY26 Guidance1 For personal use only NZ$92-100m NZ$5-8m Total Revenue Normalised EBITDA (YoY CC growth 10 – 20%) Myriad 25%+ | 1. All guidance is presented on a constant currency basis using a NZ$/US$ exchange rate of 0.60, compared to the average exchange rate of 0.59 in FY25. Constant currency rem
Slide 16: Financial Statements
For personal use only AROA BIOSURGERY | AGM Financial Statements | 17
Slide 17: Financial Statements
Financial Statements For personal use only For shareholders to ask questions on the FY25 01 financial statements or the auditor’s report. There will be an opportunity to ask general 02 questions once all items on the agenda have been considered. Further Information As there is no requirement for sha
Slide 18: General Questions
For personal use only AROA BIOSURGERY | AGM General Questions | 27
Slide 19: Thank you for attending
Thank you For personal use only for attending JAMES AGNEW investor@aroa.com VISIT www.aroa.com www.linkedin.com/company/ aroa-biosurgery-limited/ 64 Richard Pearse Drive, Auckland 2022, New Zealand PO Box 107111, Auckland Airport, Auckland 2150, New Zealand | 28
Slide 20: Normalised Profit or Loss
APPENDIX Normalised Profit or Loss For personal use only Mar-25 Mar-24 Change Change Change (CC1) NZ$000 NZ$000 NZ$000 % % Product sales 83,977 67,966 16,011 24% 21% Other revenue 720 1,100 (380) -35% -38% Total revenue 84,697 69,066 15,631 23% 20% Cost of sales (12,083) (10,093) (1,990) 20% 20% Gro
Slide 21: Normalised Cash flow
APPENDIX Normalised Cash flow1 Mar-25 Mar-24 NZ$000 NZ$000 For personal use only Cash flows from operating activities Cash receipts from sales revenue 76,648 65,247 Cash receipts from license fees, project fees, and grant income 2,032 2,763 Cash paid to suppliers and employees (82,194) (76,831) Inte
Slide 22: Balance Sheet
APPENDIX Balance Sheet Mar-25 Mar-24 NZ$000 NZ$000 Cash and cash equivalents 7,991 11,522 Term deposits 14,000 18,000 For personal use only Trade and other receivables 16,327 13,437 Inventories 8,270 8,104 Prepayments 2,405 1,816 Contract assets 18,712 15,140 Tax receivable 312 313 Financial assets